Actively Recruiting
Study of Anktiva Interleukin-15 Superagonist Nogapendekin Alfa Inbakicept Treatment for Adults With Long COVID
Led by ImmunityBio, Inc. · Updated on 2026-05-11
20
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of Anktiva, an interleukin-15 superagonist called Nogapendekin Alfa Inbakicept, in patients experiencing Long Covid symptoms. This is a Phase 2 clinical trial sponsored by ImmunityBio, Inc. The study focuses on adults aged 18 to 70 who have confirmed Long Covid characterized by specific symptoms lasting at least 60 days and impacting quality of life. Participants will receive up to two subcutaneous doses of N-803 IL-15 Superagonist during the treatment period, which lasts approximately 75 days. All patients are in a single treatment arm. The study includes follow-up visits to monitor safety, collect laboratory tests including blood counts and chemistry, and assess patient-reported outcomes related to health and quality of life. Throughout the study, participants will undergo clinical exams, laboratory assessments such as CBC and CMP, and questionnaires including PROMIS-29 and EuroQoL quality of life measures. Researchers will track adverse events, vital signs, and viral markers in blood and stool over the treatment period and up to 30 days post final dose. The total duration of participation spans around 75 days, with safety and tolerability as the main focus.
CONDITIONS
Brief Title
A Study to Assess Anktiva in Patients With Long Covid-19.
Research Team
K
Kayleigh Russell
J
Jayson Garmizo
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here